Rhythm Pharmaceuticals names Pantherx Rare for Imcivree's expanded indication.
- Pantherx Rare appointed exclusive specialty pharmacy for Imcivree
- New expanded indication for obesity-related genetic disorders
- Focus on enhancing patient access and care
Pantherx Rare has been chosen as the exclusive specialty pharmacy by Rhythm Pharmaceuticals to dispense Imcivree, a medication used to treat obesity related to genetic disorders. This partnership aims to improve access to the medication for patients in need of specialized care. The selection underscores Pantherx Rare's commitment to supporting innovative therapies in rare diseases.
Imcivree, known generically as setmelanotide, has received an expanded indication that allows treatment for additional genetic conditions associated with obesity. The collaboration is designed to enhance patient access and streamline the distribution process. This step reflects both companies' dedication to addressing the challenges faced by individuals with rare obesity-related disorders.
Through this designation, Pantherx Rare will provide patient-centric services and support that cater specifically to the needs of individuals prescribed Imcivree. The partnership focuses on optimizing care and ensuring that patients receive their medications effectively and efficiently.
